Pila Pharma aims higher: Builds pipeline and takes diabetes pill to phase III
Former Novo Nordisk researcher Dorte X. Gram, who is developing a diabetes tablet for the firm Pila Pharma, postpones her plans of selling the rights to the medication. Now, she aims at building a drug pipeline and taking the main asset through another clinical trial.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
For six years, former Novo Nordisk researcher Dorte X. Gram has been developing the diabetes tablet XEN-D0501 in the Swedish startup Pila Pharma – with the help of her son, investors, consultants and a handful of coworkers.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
